Patent intelligence · Companies
Company patent strength
Non-educational filers ranked by their patent portfolio. Grant rate and lapsed share expose where high filing volume is not matched by granted patents. Domestic filers lead — toggle to foreign applicants to see who is entering the Indian market.
Free to browse the ranking. Sign into open a filer's full profile — inventors, filing trend and quality index. See how we rank.
Why this page exists — and how to read it
Filing volume and IP quality are different things. This leaderboard ranks non-educational filers by portfolio, but the grant-rate and lapsed sorts are where the judgement lives: they separate companies whose filings survive examination from those accumulating paper.
- Investors
- High grant rate on steady filing usually means a real R&D engine; big volume with a high lapsed share is a red flag worth asking about.
- Founders & operators
- These are the incumbents and potential acquirers in your space — open a filer to see the walls you'd build against.
- Corporate & R&D
- Benchmark competitors' portfolios and grant rates; toggle to foreign to watch who is entering the Indian market.
💬 The grant-rate sort applies a 20-filing floor so tiny portfolios can't top the list.
3,207 foreign filers with 5+ patents · page 60
| # | Filer | Patents↓ | Granted↓ | Lapsed↓ | Pending↓ | Active |
|---|---|---|---|---|---|---|
| 2951 | MEDIBEACON | 5 | 00% | 0 | 5 | 2022–2025 |
| 2952 | MEDIKINE | 5 | 00% | 0 | 5 | 2022–2023 |
| 2953 | MEDSPRAY | 5 | 00% | 0 | 5 | 2023–2025 |
| 2954 | MEDTRONIC | 5 | 120% | 0 | 4 | 2021–2025 |
| 2955 | MELD MANUFACTURING | 5 | 00% | 0 | 5 | 2023–2025 |
| 2956 | MEMBION | 5 | 120% | 0 | 4 | 2022–2024 |
| 2957 | MEMMINGER IRO GESELLSCHAFT MIT BESCHR NKTER HAFTUNG | 5 | 00% | 0 | 5 | 2024–2025 |
| 2958 | MERCK MILLIPORE | 5 | 360% | 0 | 2 | 2022–2024 |
| 2959 | MERLYN MIND | 5 | 00% | 1 | 4 | 2022–2024 |
| 2960 | META PLATFORMS | 5 | 120% | 0 | 4 | 2020–2023 |
| 2961 | META PLATFORMS TECHNOLOGIES | 5 | 00% | 1 | 4 | 2022–2023 |
| 2962 | METALOGENIA RESEARCH TECHNOLOGIES S L | 5 | 00% | 0 | 5 | 2023–2024 |
| 2963 | MEYER BURGER SWITZERLAND | 5 | 120% | 1 | 3 | 2022–2025 |
| 2964 | MICROBOT MEDICAL | 5 | 00% | 0 | 5 | 2023–2024 |
| 2965 | MINEBEA ACCESSSOLUTIONS | 5 | 00% | 0 | 5 | 2023–2025 |
| 2966 | MINER ENTERPRISES | 5 | 00% | 0 | 5 | 2022–2024 |
| 2967 | MINGHUI PHARMACEUTICAL HANGZHOU | 5 | 00% | 0 | 5 | 2023–2026 |
| 2968 | MITSUBISHI KAKOKI KAISHA | 5 | 00% | 0 | 5 | 2023–2026 |
| 2969 | MOLEAER | 5 | 00% | 2 | 3 | 2022–2025 |
| 2970 | MOMENTA PHARMACEUTICALS | 5 | 00% | 2 | 3 | 2022–2023 |
| 2971 | MONDI | 5 | 00% | 1 | 4 | 2022–2025 |
| 2972 | MONT INVEST 30 AS | 5 | 120% | 0 | 4 | 2021–2026 |
| 2973 | MONTE ROSA THERAPEUTICS | 5 | 00% | 0 | 5 | 2023–2026 |
| 2974 | MOTAN HOLDING | 5 | 00% | 1 | 4 | 2022–2025 |
| 2975 | MULTITUDE THERAPEUTICS | 5 | 00% | 0 | 5 | 2024–2025 |
| 2976 | MUNTERS | 5 | 00% | 0 | 5 | 2024–2025 |
| 2977 | MUSASHI ENGINEERING | 5 | 00% | 0 | 5 | 2022–2026 |
| 2978 | MYTHIC THERAPEUTICS | 5 | 00% | 0 | 5 | 2022–2025 |
| 2979 | NBC MESHTEC | 5 | 00% | 0 | 5 | 2023–2025 |
| 2980 | NECTIN THERAPEUTICS | 5 | 00% | 0 | 5 | 2022–2025 |
| 2981 | NEW IRIDIUM | 5 | 00% | 2 | 3 | 2022–2026 |
| 2982 | NEWTECH TEXTILE TECHNOLOGY DEVELOPMENT SHANGHAI | 5 | 120% | 0 | 4 | 2022–2025 |
| 2983 | NEXII BUILDING SOLUTIONS | 5 | 00% | 2 | 3 | 2022–2024 |
| 2984 | NHV | 5 | 00% | 0 | 5 | 2023–2026 |
| 2985 | NICHIAS | 5 | 120% | 1 | 3 | 2022–2026 |
| 2986 | NIKANG THERAPEUTICS | 5 | 00% | 1 | 4 | 2022–2025 |
| 2987 | NIPPON MUKI | 5 | 00% | 0 | 5 | 2022–2025 |
| 2988 | NISSHINBO CHEMICAL | 5 | 240% | 1 | 2 | 2022–2023 |
| 2989 | NISSIN ELECTRIC | 5 | 240% | 0 | 3 | 2023–2025 |
| 2990 | NISSUI | 5 | 00% | 0 | 5 | 2023–2026 |
| 2991 | NITTA GELATIN | 5 | 120% | 0 | 4 | 2022–2026 |
| 2992 | NOCION THERAPEUTICS | 5 | 240% | 0 | 3 | 2022–2024 |
| 2993 | NODTHERA | 5 | 00% | 0 | 5 | 2023–2025 |
| 2994 | NOGRA PHARMA | 5 | 00% | 1 | 4 | 2022–2025 |
| 2995 | NORTHROP GRUMMAN LITEF | 5 | 00% | 0 | 5 | 2024–2025 |
| 2996 | NUCTECH | 5 | 120% | 0 | 4 | 2023–2026 |
| 2997 | NURITAS | 5 | 00% | 0 | 5 | 2022–2022 |
| 2998 | NUVOTON TECHNOLOGY JAPAN | 5 | 00% | 0 | 5 | 2024–2026 |
| 2999 | NVH KOREA | 5 | 120% | 0 | 4 | 2022–2025 |
| 3000 | NYOBOLT | 5 | 120% | 0 | 4 | 2022–2026 |
Educational institutes are excluded — see the institute leaderboard. Attribution is by patent assignee record; a jointly-owned patent is credited to each co-owner, so a co-filed patent counts for every company on it. "Lapsed" = abandoned, withdrawn, deemed-withdrawn or refused; "Pending" = awaiting examination or in prosecution. Want to filter by technology or value category? Browse the filer explorer →
Rankings use patent-registry status (grant rate, examination, claim depth) as a quality proxy — directional, not advice; see methodology. Read the ranking methodology →